Dr. Chapman From Memorial Sloan-Kettering Cancer Center Describes Recent Melanoma Advances
Paul Chapman, MD, From Memorial Sloan-Kettering Cancer Center describes recent melanoma advances.
Dr. Chapman says there are now two drugs that improve survival in patients with metastatic melanoma. He adds that this has never happened before in melanoma because only two years ago there was no drug that was shown to improve survival in patients. He says physicians now have choices. While the drugs still need to be improved, they are a start and something that can be built upon in terms of combination therapies.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making